Haixi Pharma Buys 0.50% of Outstanding H-Shares for Incentive Scheme Implementation

Bulletin Express10-20

Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) announced that, as of 16 October 2026, the trustee of its Share Incentive Scheme has acquired 394,900 H-shares on the Hong Kong Stock Exchange, equal to approximately 0.502% of the company’s total issued share capital.

The purchased shares will be held in trust for eligible participants and allocated in future grants under the approved Share Incentive Scheme. Share buybacks will continue at the Board’s discretion, subject to market conditions. The company emphasized that there is no assurance regarding the timing, quantity or price of any additional purchases.

The initiative was endorsed on 27 May 2026 via special resolution at the annual general meeting following the publication of the scheme proposal on 29 April 2026 and related circular on 30 April 2026. Haixi Pharma will release further updates in accordance with Hong Kong listing rules.

Investors are advised to exercise caution when trading the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment